Pasar al contenido principal

Advancing science. 

Empowering startups. 

Transforming healthcare.

Why an advanced therapies accelerator?

Advanced therapies represent the future of medicine, offering more specific, customizable, and effective treatments. To strengthen the health innovation ecosystem, foster the creation of new companies, and support their growth with the goal of positioning Catalonia as a benchmark in the development of advanced therapies, Biocat is launching ATMP Catalyst, the first acceleration program for advanced therapies in Catalonia. The goal is to enhance the existing advanced therapies ecosystem in the BioRegion, increasing both the quality and quantity of projects and companies dedicated to these innovative therapies.

Check the ATMP Catalyst program
What can you expect?

The most complete accelerator of advanced therapies

The projects and/or startups that become part of ATMP Catalyst will have:

Subsidized workspaces

Participants have the opportunity to access spaces at Leitat and the Barcelona Scientific Park (PCB-UB), tailored to the needs of the projects.

Mentoring

Leading professionals in the advanced therapies sector, with experience in key areas such as regulation, intellectual property, market access, business models, and clinical development

Training

25 hours of theoretical training complemented with two practical case studies and the opportunity to have individualized sessions with experts from the ecosystem.

Networking and visibility

Connections with investors, public-private collaboration opportunities, and international projection through Biocat's network and initiatives.

Phases and Training Program

Phase I | Basic research and proof of concept

Objectives: 

  • Formulation of the technological concept. 
  • Development of initial prototypes. 
  • Initial in vitro preclinical studies. 
  • Evaluation of technical feasibility and collection of scientific documentation.

Training Program:

  • Regulatory roadmap
  • Market acces
  • Intellectual property
  • Financing

6 months to move from TRL 2-3 to TRL 3-4. 

Phase II | PoC – Preclinical development

Objectives: 

  • Validation of the experimental proof of concept. 
  • Development of advanced prototypes. 
  • Validation of the mechanism of action.
  • Preliminary safety assessment.
  • Preparation of documentation and scientific reports.

Training Program:

  • Identification of specific regulatory requirements
  • Market feasibility study and identification of potential clients
  • Legal protection through patents or copyrights
  • Seeking new funding sources to advance the research

 

1 year – TRL 3-4

Phase III | Preclinical Development

Objectives: 

  • Technological validation in laboratories. 
  • Determination of the regulatory and scaling strategy.
  • Preparation of clinical trial design. 
  • Preliminary regulatory interactions.

Training Program:

  • Regulatory compliance to advance toward clinical trials.
  • Establishment of market entry strategies.
  • Expansion of intellectual property protection.
  • Securing funding for next development phases.

1 year – TRL 4-5

Want more information? Contact us now!

Partners

An initiative of

Co-organized by

With the collaboration of

Suscríbete a nuestras newsletters

Toda la actualidad de Biocat y del sector de las ciencias de la vida y la salud en tu badeja de entrada.